LÖSEV Hospital Brings CAR-T Cell Therapy to Türkiye for Leukemia and Blood Cancer Patients
LÖSEV hospital is set to introduce CAR-T cell therapy in Türkiye, offering new hope for leukemia and other blood cancer patients. This advanced treatment, described by Professor Dr. Günhan Gürman as continuously evolving, has shown promising results abroad and could contribute to cancer vaccine development.
CAR-T therapy involves reprogramming a patient's own immune cells to recognize and attack cancer cells. Professor Dr. Ahmet Emin Kürekçi explained that this process equips T lymphocytes with receptors to identify cancer cell proteins. Once reprogrammed, these cells are trained in the lab to destroy cancer. Leukemias, the most common cancers in children with around 1,500 cases annually in Türkiye, could significantly benefit from this treatment. Decades of medical advances have steadily increased survival rates for leukemia, and CAR-T therapy is the next step in this progress.
LÖSEV hospital is preparing to introduce CAR-T cell therapy for leukemia and other blood cancers in Türkiye. This advanced treatment, which has shown promising results abroad, offers hope for patients and their families. With the potential to enhance both prevention and treatment, CAR-T therapy could significantly impact cancer care in the country.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
- Various forms of cataracts include nuclear, pediatric, traumatic, and additional types
